Skip to main content

Dyadic Extends Scripps Fungal Genomics Collaboration

NEW YORK (GenomeWeb News) – Dyadic International has extended a collaboration with The Scripps Research Institute under which Scripps will re-annotate the genome of Dyadic's C1 fungus.

The company said that it has re-sequenced the C1 fungus that Scripps first annotated under a collaboration that began in 2006.

The results of that project and advances Dyadic has made have given the company the ability to develop new enzyme products and solutions and to develop the C1 platform, which it has licensed to Abengoa Bioenergy New Technologies and Codexis for use in enzyme and protein production.

The re-annotated genome "will provide Dyadic and its commercial partners with a more accurate blueprint of the C1 fungal strain," Dyadic's CEO Mark Emalfarb said in a statement.

"Our expertise in informatics, data analysis and software engineering, when combined with the C1 fungal genome should yield a powerful resource for understanding gene function, and development of important enzymes," Bruce Pascal, a principal investigator at Scripps Florida, added.

Financial terms of the agreement were not released.

The Scan

Pfizer-BioNTech Seek Full Vaccine Approval

According to the New York Times, Pfizer and BioNTech are seeking full US Food and Drug Administration approval for their SARS-CoV-2 vaccine.

Viral Integration Study Critiqued

Science writes that a paper reporting that SARS-CoV-2 can occasionally integrate into the host genome is drawing criticism.

Giraffe Species Debate

The Scientist reports that a new analysis aiming to end the discussion of how many giraffe species there are has only continued it.

Science Papers Examine Factors Shaping SARS-CoV-2 Spread, Give Insight Into Bacterial Evolution

In Science this week: genomic analysis points to role of human behavior in SARS-CoV-2 spread, and more.